Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Aged 12 to 65 years inclusive~* Minimum weight 45kg~* Clinical features of severe refractory asthma~* Well documented requirement for high dose inhaled corticosteroids (ICS) \[i.e. \>= 880mcg/day fluticasone propionate or equivalent daily\] for at least 12 months~* Using additional controller medication in addition to high dose ICS for at least 12 months~* Persistent airflow obstruction indicated by a pre-bronchodilator FEV1\<80% predicted at visit 1 or 2 or peak flow diurnal variability of \>20% on 3 or more days during the run-in~* Airway inflammation which is likely to be eosinophilic in nature demonstrated by either raised peripheral blood eosinophils (\>=300/microL), sputum eosinophils (\>=3%), exhaled nitric oxide (\>=50ppb) or prompt deterioration of asthma control following a \<=25% reduction in regular maintenance dose of inhaled or oral corticosteroids (OCS)~* History of 2 or more exacerbations requiring systemic corticosteroids in the previous 12 months~* Evidence of asthma documented by airway reversibility, airway hyperresponsiveness or airflow variability~* ECG assessment demonstrating QTc\<450msec or QTc\<480msec for patients with bundle branch block~* Liver function tests demonstrating ALT\<2xUpper Limit of Normal (ULN), AST\<2xULN, Alk Phos \<=1.5xULN, bilirubin \<=1.5xULN~* Female of non-child-bearing potential or child-bearing potential with a negative pregnancy test at screening and prepared to agree to an acceptable method of contraception~* Able to give written informed consent~* Able to read, comprehend and write at a sufficient level to complete study materials~Exclusion Criteria:~* Current smokers or smoking history of \>=10 pack years~* Clinically important lung condition other than asthma~* Diagnosis of malignancy or in the process of investigation~* Unstable liver disease~* Churg-Strauss syndrome~* Using methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any experimental anti-inflammatory therapy within 3 months of screening~* Omalizumab (Xolair) or any other biological for the treatment of inflammatory disease within 6 months of Visit 1~* Regular use of oral or systemic corticosteroids for diseases other than asthma within 12 months or any intra-articular, short-acting intramuscular corticosteroid within 1 month or intramuscular, long-acting depot corticosteroid within 3 months~* Allergy/intolerance to the excipients in the mepolizumab formulation~* Any investigational drug within 30 days or 5 terminal half-lives, whichever is longer~* Pregnant or breastfeeding or planning to become pregnant~* Clinically significant disease which is uncontrolled with standard treatment~* History of alcohol misuse or substance abuse~* Parasitic infestation within previous 6 months~* Known immunodeficiency~* Unable to follow instructions, use the electronic diary or peak flow meter~* Known evidence of lack of adherence to controller medications and/or follow physician's recommendations~* Previous participation in a study of mepolizumab and received study medication within 90 days

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mepolizumab 750mg (Type: ACTIVE_COMPARATOR): Mepolizumab 750mcg i.v. every 4 weeks
- Mepolizumab 250mg (Type: ACTIVE_COMPARATOR): Mepolizumab 250mcg i.v. every 4 weeks
- Mepolizumab 75mg (Type: ACTIVE_COMPARATOR): Mepolizumab 75mcg i.v. every 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo saline every 4 weeks i.v.

Based on this trial design, predict the completion outcome and termination type (if applicable).